UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
_____________
FORM
8-K
_____________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
report (Date of earliest event reported): May
4, 2005
Keryx
Biopharmaceuticals, Inc.
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
(State
or Other Jurisdiction
of
Incorporation) |
000-30929
(Commission
File Number) |
13-4087132
(IRS
Employer Identification No.) |
750
Lexington Avenue
New
York, New York 10022
(Address
of Principal Executive Offices)
(212)
531-5965
(Registrant's
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
| £ |
Written
communications pursuant to Rule 425 under the Securities
Act. |
| £ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange
Act. |
| £ |
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange
Act. |
| £ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act. |
Item
2.02. Results of Operations and Financial Condition
On May 4,
2005, Keryx Biopharmaceuticals, Inc. (“Keryx”) issued a press release announcing
results of operations for the first quarter ended March 31, 2005. Keryx also
announced that it would host a conference call on May 6, 2005, for investors
where Keryx will discuss its results of operations and financial results. A copy
of such press release is being furnished as Exhibit 99.1 to this report.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
|
| |
Keryx Biopharmaceuticals,
Inc.
(Registrant) |
|
|
|
| Date: May 4, 2005 |
By: |
/s/ Ron Bentsur |
| |
Ron Bentsur
Vice President, Finance and Investor
Relations |
INDEX
TO EXHIBITS
Exhibit
Number
Description
99.1
Press
Release dated May 4, 2005.